Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Allurion Technologies, Inc. (ALUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: ALUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.62
1 Year Target Price $10.62
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.66% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.27M USD | Price to earnings Ratio - | 1Y Target Price 10.62 |
Price to earnings Ratio - | 1Y Target Price 10.62 | ||
Volume (30-day avg) 4 | Beta -0.51 | 52 Weeks Range 2.15 - 31.50 | Updated Date 07/2/2025 |
52 Weeks Range 2.15 - 31.50 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -86.05% | Operating Margin (TTM) -130.5% |
Management Effectiveness
Return on Assets (TTM) -52.2% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 30838507 | Price to Sales(TTM) 0.65 |
Enterprise Value 30838507 | Price to Sales(TTM) 0.65 | ||
Enterprise Value to Revenue 1.09 | Enterprise Value to EBITDA -2.15 | Shares Outstanding 7457760 | Shares Floating 3680180 |
Shares Outstanding 7457760 | Shares Floating 3680180 | ||
Percent Insiders 11.67 | Percent Institutions 46.23 |
Upturn AI SWOT
Allurion Technologies, Inc.
Company Overview
History and Background
Allurion Technologies, Inc. focuses on developing innovative solutions for weight loss. Founded in 2009, it gained prominence with its swallowable gastric balloon program.
Core Business Areas
- Weight Loss Program: Allurion's flagship product is a weight-loss program centered on its swallowable gastric balloon, coupled with nutritional and lifestyle support. The Allurion Program provides access to a mobile app, connected scale, and health tracker.
Leadership and Structure
The leadership team is headed by its Chief Executive Officer. The structure comprises departments for R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- Allurion Program: The Allurion Program features a swallowable gastric balloon inserted without surgery, endoscopy, or anesthesia, coupled with a lifestyle change program, supported by connected tools and virtual care. Revenue is largely derived from the Allurion Program. Competitors include other medical weight loss programs and bariatric surgeries. There is no specific market share available, as this is a niche segment of weight loss.
Market Dynamics
Industry Overview
The weight loss industry is driven by the increasing prevalence of obesity and related health concerns. It includes diet programs, weight loss surgeries, medical devices, and pharmaceuticals.
Positioning
Allurion positions itself as a non-surgical weight loss solution, differentiating from bariatric surgery and intensive medical interventions.
Total Addressable Market (TAM)
The global weight management market is expected to reach hundreds of billions of dollars. Allurion targets a segment of this market, focusing on individuals seeking less invasive weight loss options.
Upturn SWOT Analysis
Strengths
- Non-surgical approach
- Innovative technology (swallowable balloon)
- Comprehensive program (balloon + support)
- Global presence
Weaknesses
- Cost compared to diet programs
- Reliance on program adherence
- Potential side effects
- Limited long-term data
Opportunities
- Expanding into new markets
- Developing new products
- Partnerships with healthcare providers
- Increased awareness of non-surgical options
Threats
- Competition from other weight loss methods
- Regulatory changes
- Economic downturn
- Negative publicity
Competitors and Market Share
Key Competitors
- ResMed (RMD)
- Novo Nordisk (NVO)
- Intuitive Surgical (ISRG)
Competitive Landscape
Allurion's advantage is its non-surgical approach. Disadvantages include cost and the need for patient compliance.
Growth Trajectory and Initiatives
Historical Growth: The growth rate is dependent on market adoption and expansion into new regions.
Future Projections: Future growth is dependent on analyst estimates and company guidance which can be located on the company's IR page.
Recent Initiatives: Recent strategic initiatives typically include market expansion, product development, and partnerships.
Summary
Allurion Technologies, Inc. offers an innovative, non-surgical weight loss solution with global reach. Its strengths lie in its unique technology and comprehensive program, but it faces challenges related to cost, patient compliance, and competition. Future success depends on expanding into new markets, developing new products, and forging strategic partnerships. However the smaller market share will need to increase for better margins and ROI for shareholders
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allurion Technologies, Inc.
Exchange NYSE | Headquaters Natick, MA, United States | ||
IPO Launch date 2023-08-02 | Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Dr. Shantanu K. Gaur M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 134 | Website https://www.allurion.com |
Full time employees 134 | Website https://www.allurion.com | ||
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.